In 2003, the ACTL technical team received a doctor, but he did not come to see the patient, but to find a new treatment for his disease.

Dr. Zhang was diagnosed with non-small cell lung adenocarcinoma-the most common type of lung cancer. At the time of diagnosis, it was already at an advanced stage and no indication for surgical treatment was lost. At that time, the only clinical option was chemotherapy. Dr. Zhang, who was well versed in chemotherapy, immediately rejected chemotherapy after confirming his diagnosis. After being introduced by a colleague, I got in touch with the ACTL technical team.

According to Dr. Zhang's condition, the ACTL technical team recommended that he receive chemotherapy, combined with ACTL treatment, so that the effect will be better. But Dr. Zhang insisted not to do chemotherapy, only ACTL. The technical team can only respect the opinions of Dr. Zhang himself. The hospital tested him for blood tumor markers and used immunohistochemistry to detect target antigens in tumor tissues.

"Similar to Dr. Zhang's condition, it is usually recommended to use other treatments to reduce the tumor burden as much as possible, and then adopt a comprehensive treatment plan such as ACTL. Using ACTL alone, we were really not sure what the result would be," a member of the ACTL technical team recalled.

The examination results showed that Dr. Zhang’s blood carcinoembryonic antigen (CEA) and cyfra21-1 antigen were positive, and the tumor tissue’s survivin antigen (Survivin), melanoma-associated antigen-A3 (MAGE-A3), and prostate specific membrane antigen (PSMA) were positive Positive. These five antigens are clear targets for ACTL treatment, so Dr. Zhang embarked on his anti-cancer "adventure journey".

Due to the serious illness, the ACTL technical team designed a set of "impact therapy" for Dr. Zhang-three treatments per month, and close clinical observations. Dr. Zhang responded well to the treatment with no obvious side effects. He felt that his mental state had improved significantly, and his years of insomnia had also improved significantly.

After 9 treatments in three months, CT scans found that the lung lesions were reduced by a quarter, and the condition showed a trend of improvement. This completely exceeded the expectations of the technical team.

The ACTL technical team considered it unnecessary to continue to use "impact therapy" and decided to change the treatment plan from the original three treatments per month to twice a month. Doctor Zhang's condition continued to improve.

After two years of treatment, Dr. Zhang's condition improved significantly, and most of the lung lesions disappeared. Below is a comparison chart before and after treatment.

Members of the ACTL technical team were particularly excited when talking about the case: “We never thought that using ACTL alone could make Dr. Zhang’s condition so much improved. The effect is obvious to all, and this case makes us more convinced that we are on the right path. Come on. ACTL can help more patients!"

Dr. Zhang has survived after ACTL treatment. Although the blood CEA level is still high, no signs of recurrence have been found in regular examinations for many years.

The traditional methods of treating lung cancer are mainly through surgery, chemotherapy and radiotherapy, but they often damage normal cells and cause mild or severe side effects. ACTL treatment can accurately identify cancer cells, accurately kill cancer cells remaining in the body after surgery, radiotherapy or chemotherapy, and prevent recurrence and spread; it can also reverse the patient’s resistance to targeted drugs and endocrine drugs, and prolong the patient’s recovery from these types of drugs. Time to benefit from the medicine. The view of modern tumor treatment is individualized comprehensive treatment. Years of clinical practice have shown that ACTL combined with other treatment methods will have better treatment effects.